drugset / Trial / NCT05576909
Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation
Phase 2
Unknown
20 enrolled
Beijing Tsinghua Chang Gung Hospital
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of the combination of donafenib and TACE in the perioperative period of liver transplantation.
Timeline
- Start
- 2023-03-30
- Primary completion
- 2024-10-15
- Completion
- 2025-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donafenib | Small molecule | 0.1 g | — |